Targeting Bruton's Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges. [PDF]
Torke S, Dybowski S, Weber MS.
europepmc +1 more source
Targeting Bruton's Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]
Bravo E +4 more
europepmc +1 more source
Visualization of a Bruton's Tyrosine Kinase Inhibitor Using Fluorescence and Raman Microscopy. [PDF]
Merchant AS +3 more
europepmc +1 more source
A Novel Bruton's Tyrosine Kinase Inhibitor Suppresses Pancreatic Neuroendocrine Neoplasms Progression via ATF3-Induced Ferroptosis. [PDF]
Hu P +10 more
europepmc +1 more source
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures". [PDF]
Darragh AC +5 more
europepmc +2 more sources
Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease. [PDF]
Ye Q, Ma S.
europepmc +1 more source
Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]
Woudberg R, Sinanovic E.
europepmc +1 more source
Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]
Hujjat SFZ +4 more
europepmc +1 more source
Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]
Lu C +6 more
europepmc +1 more source
Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. [PDF]
AlRammah T +7 more
europepmc +1 more source

